Equities

Matinas BioPharma Holdings Inc

Matinas BioPharma Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.746
  • Today's Change-0.154 / -17.11%
  • Shares traded448.19k
  • 1 Year change-93.00%
  • Beta1.7799
Data delayed at least 15 minutes, as of Nov 13 2024 01:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform0
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Matinas BioPharma Holdings Inc share price to rise to 30.00 in the next year from the last price of 0.746.
High3,921.4%30.00
Med3,921.4%30.00
Low3,921.4%30.00

Earnings history & estimates in USD

On Aug 14, 2024, Matinas BioPharma Holdings Inc reported 2nd quarter 2024 losses of -1.00 per share. This result exceeded the -1.25 consensus loss of the 2 analysts covering the company and exceeded last year's 2nd quarter results by 33.33%.
The next earnings announcement is expected on Nov 12, 2024.
Average growth rate+4.17%
Matinas BioPharma Holdings Inc reported annual 2023 losses of -5.50 per share on Mar 27, 2024.
Average growth rate+3.78%
More ▼

Revenue history & estimates in USD

Matinas BioPharma Holdings, Inc. did not report revenues for the 2nd quarter 2024. However, during the 2nd quarter of the prior year the company reported revenues of 1.10m.
Average growth rate0.00%
Matinas BioPharma Holdings, Inc. had revenues for the full year 2023 of 1.10m. This was 65.62% below the prior year's results.
Average growth rate+2,372.86%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.